Search results
Regeneron misses earnings, revenue expectations By Investing.com
Investing.com· 2 days agoRegeneron (NASDAQ:REGN) experienced a slight decline in its stock price, falling 1.82% after...
Regeneron records mixed results for Q1 as Eylea revenues fall
Crain's New York Business· 1 day agoThe slight dip was driven by decreases in sales of one eye disease drug, Eylea. While Schott predicted that the macular degeneration therapy would bring in $2.2 billion in sales, the medication ...
Regeneron, Lilly grapple with clinical endpoints as obesity space moves to improving weight loss
FierceBiotech· 2 days agoThe approved GLP-1 medicines, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, are known to cause...
Regeneron Pharma earnings missed by $0.64, revenue fell short of estimates
Investing.com· 2 days agoRegeneron Pharma earnings missed by $0.64, revenue fell short of estimates
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Trans
Guru Focus· 2 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Regeneron Pharmaceuticals Inc (REGN, Financial) reported a solid start ...
Truist Financial Corp Sells 8,062 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 5 days agoTruist Financial Corp reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 15.4% in the fourth quarter, according to the company ...
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks· 2 days agoAlthough the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics ...
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Zacks via Yahoo Finance· 5 days agoEvaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking...
Regeneron’s stock rallies as pipeline prospects outweigh earnings miss
Market Watch· 2 days agoThe revenue shortfall was partly due to a decline in sales of the company’s blockbuster eye drug...
UPDATE 3-Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Reuters via Yahoo Finance· 2 days ago(Adds details on Eylea sales miss in paragraph 2, consensus estimates for Eylea 8mg in paragraph 5) May 2 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall ...